JY
BBIO icon

Jeff Yass’s BridgeBio Pharma BBIO Stock Holding History

Jeff Yass’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195M Buy
2,620,200
+235,600
+10% +$16.5M 0.02% 602
2026
Q1 		$177M Sell
2,384,600
-285,700
-11% -$20.7M 0.02% 566
2025
Q4 		$204M Sell
2,670,300
-308,100
-10% -$20.2M 0.02% 531
2025
Q3 		$155M Buy
2,978,400
+41,300
+1% +$2.01M 0.02% 647
2025
Q2 		$127M Sell
2,937,100
-168,400
-5% -$6.12M 0.02% 631
2025
Q1 		$107M Sell
3,105,500
-400,100
-11% -$13.5M 0.02% 621
2024
Q4 		$96.2M Buy
3,505,600
+367,600
+12% +$9.5M 0.01% 738
2024
Q3 		$79.9M Buy
3,138,000
+146,800
+5% +$3.85M 0.01% 774
2024
Q2 		$75.8M Buy
2,991,200
+1,985,600
+197% +$54.3M 0.01% 730
2024
Q1 		$31.1M Buy
1,005,600
+261,000
+35% +$8.88M 0.01% 1376
2023
Q4 		$30.1M Buy
744,600
+103,700
+16% +$3.11M 0.01% 1407
2023
Q3 		$16.9M Sell
640,900
-203,400
-24% -$5.77M ﹤0.01% 1928
2023
Q2 		$14.5M Buy
844,300
+603,100
+250% +$9.07M ﹤0.01% 2063
2023
Q1 		$4M Buy
241,200
+186,200
+339% +$2.17M ﹤0.01% 3796
2022
Q4 		$419K Buy
55,000
+31,000
+129% +$297K ﹤0.01% 8302
2022
Q3 		$239K Sell
24,000
-247,100
-91% -$2.57M ﹤0.01% 10386
2022
Q2 		$2.46M Buy
271,100
+112,600
+71% +$942K ﹤0.01% 4463
2022
Q1 		$1.61M Sell
158,500
-666,700
-81% -$6.84M ﹤0.01% 5967
2021
Q4 		$13.8M Buy
825,200
+761,900
+1,204% +$32.2M ﹤0.01% 2287
2021
Q3 		$2.97M Sell
63,300
-20,400
-24% -$1.09M ﹤0.01% 4984
2021
Q2 		$5.1M Sell
83,700
-21,300
-20% -$1.22M ﹤0.01% 4006
2021
Q1 		$6.47M Buy
105,000
+26,700
+34% +$1.75M ﹤0.01% 3450
2020
Q4 		$5.57M Buy
78,300
+65,500
+512% +$3.16M ﹤0.01% 3249
2020
Q3 		$480K Sell
12,800
-294,300
-96% -$9.26M ﹤0.01% 7768
2020
Q2 		$10M Buy
307,100
+105,900
+53% +$3.23M ﹤0.01% 2134
2020
Q1 		$5.83M Buy
+201,200
New +$6.24M ﹤0.01% 2384

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Jeff Yass's BBIO Position: Q2 2026 in Review

Jeff Yass increased its BridgeBio Pharma (BBIO) stake by 64% in Q2 2026, buying an estimated $17.8M and bringing the position to 653,224 shares worth $48.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Jeff Yass first reported a position in BBIO in Q3 2019 and has held it in 27 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Jeff Yass held 653,224 shares of BridgeBio Pharma worth $48.7M as of Q2 2026.
  • Jeff Yass bought 254,281 BridgeBio Pharma shares in Q2 2026, an estimated $17.8M.
  • BridgeBio Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #1526 holding.
  • Jeff Yass first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 27 quarters since.
  • 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.